Champions Oncology, Inc.
About Us
Champions Oncology Second Quarter 2023 Earnings: US$0.001 loss per share (vs US$0.021 profit in 2Q 2022)
Case Study: Champions TumorGraft® Guides the Development of a Novel, Selective Dual BRAF/EGFR Inhibitor, CEP-32496
Champions Oncology and BGI Americas Announce a Strategic Partnership to provide Mass Spectrometry Proteomics, Metabolomics, and multi-omic Data Analysis Solutions
ChampionsOncology (@ChampionsOncol1) / Twitter
Champions Oncology - Crunchbase Company Profile & Funding
Champions Oncology (CSBR) - 6 Price Charts 2007-2022 (History)
Champions Oncology Culture | Comparably
ChampionsOncology (@ChampionsOncol1) / Twitter
Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competition at Bio-IT World Conference & Expo
ChampionsOncology (@ChampionsOncol1) / Twitter
ChampionsOncology (@ChampionsOncol1) / Twitter
Champions Oncology (ChampsOnco) - Profile | Pinterest
CHAMPIONS ONCOLOGY, INC. : CSBR Stock Price | US15870P3073 | MarketScreener
Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus
Champions Oncology, Inc. | LinkedIn
Champions Oncology
Champions Oncology and Cyclica Partnership - Cyclica
Champions Oncology Company Profile: Stock Performance & Earnings | PitchBook
Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competition at Bio-IT World Conference & Expo
Champions Oncology | Public Marketplace
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022
Champions Oncology - CJ Yu is a Senior Scientist at Champions Oncology. His role involves analyzing biomarkers within patient cancer tissues. He is passionate about integrating new technologies in his research. Learn
ChampionsOncology (@ChampionsOncol1) / Twitter
